Metabolic Effects of Modified-Release Hydrocortisone Versus Short Acting Conventional Oral Glucocorticoids in Adrenal Insufficiency: A Systematic Review and Meta-Analysis.

Clin Endocrinol (Oxf)Apr 28, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Mohammad Ehab Abdelsattar, Mai Abdallah, Ola Khaled et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the metabolic effects of modified-release hydrocortisone (MR-HC) compared to conventional glucocorticoids in patients with adrenal insufficiency. Analyzing data from six studies involving 400 participants, MR-HC was associated with significant reductions in BMI (-1.1) and waist circumference (-5.03), along with improvements in lipid profile and blood pressure, while glucose metabolism remained unchanged.

Key findings

  • MR-HC reduced BMI by a mean difference of -1.1.
  • Waist circumference decreased by -5.03 with MR-HC.
  • Total cholesterol levels dropped by -10.64 with MR-HC.
  • Systolic blood pressure was lower by -6.03 with MR-HC.

Why it matters

The findings suggest that MR-HC may offer better metabolic control and safety compared to conventional glucocorticoids, potentially improving adherence and long-term health outcomes in patients with adrenal insufficiency.

Source

PubMed · PMID 42050347Free full text on PubMed Central

Published in Clin Endocrinol (Oxf). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.